Stockreport

Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez [CNBC]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Seamus Fernandez, Guggenheim managing director, joins ‘Power Lunch' to discuss the battle between Novo Nordisk and Eli Lilly. [Read more]